Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1474 - Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)


10 Oct 2016


Poster display


Volkmar Mueller


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


V. Mueller1, M. Dank2, S. de Ducla3, L. Mitchell4, A. Schneeweiss5

Author affiliations

  • 1 Department Of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 2 Oncology Division, Semmelweis University Cancer Center, Budapest/HU
  • 3 Pharma Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel/CH
  • 4 Pharma Development Medical Affairs Biometrics, F. Hoffmann-La Roche Ltd, Basel/CH
  • 5 Division Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg/DE


Abstract 1474


Real-world data exploring effectiveness of treatments following demonstrated efficacy in phase III trials are becoming increasingly important, especially for regulatory bodies and payers. Pooling outcome and adverse-event (AE) data from non-interventional studies enables more accurate estimation of real-world effectiveness and safety in clinically important subgroups.


Individual pt data from pts receiving first-line BEV + PAC with no additional chemotherapy agent for HER2-negative mBC in three non-interventional studies (ML21165 [Germany], AVANTI [Germany] and AVAREG [Hungary]) were extracted and pooled. Progression-free survival (PFS) and overall survival (OS) were estimated in the BEV + PAC population and subgroups of clinical interest by Kaplan-Meier methodology. Safety was analysed descriptively.


The analysis population included 2135 pts. The median duration of follow-up was 13.1 (range


Results from >2000 pts treated in the real-world setting indicate effectiveness of first-line BEV + PAC in HER2-negative mBC. The main limitation of this analysis is the inconsistent data collection and recording between studies. Nevertheless, this approach provides insight into effectiveness of BEV + PAC in the real-world setting.

Clinical trial identification


Legal entity responsible for the study

F Hoffmann-La Roche


F Hoffmann-La Roche


V. Mueller: VM has received speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, GlaxoSmithKline, Pfizer, Pierre-Fabre, Novartis, Roche, Teva and Janssen-Cilag, and consultancy honoraria from Roche, Pierre Fabre, Amgen and Eisai. S. de Ducla: SdD is an employee of Roche and holds shares in Roche. L. Mitchell: LM is a full-time employee of Roche with all conditions/benefits under Roche's contract. A. Schneeweiss: AS has received honoraria from Roche and Celgene for several talks and research funding from Celgene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings